These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 34475375)
1. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Fan J; Zhuang X; Yang X; Xu Y; Zhou Z; Pan L; Chen S Signal Transduct Target Ther; 2021 Sep; 6(1):320. PubMed ID: 34475375 [No Abstract] [Full Text] [Related]
2. A comparative study and evaluation of anti-EGFR nanobodies expressed in Pichia pastoris and Escherichia coli as antitumor moieties. Xi X; Sun W; Li H; Fan Q; Zhang X; Sun F Protein Expr Purif; 2021 Aug; 184():105888. PubMed ID: 33857600 [TBL] [Abstract][Full Text] [Related]
3. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma. Tao Y; Wang R; Lai Q; Wu M; Wang Y; Jiang X; Zeng L; Zhou S; Li Z; Yang T; Yao Y; Wu Y; Yu L; Fu Y; Lai W; Peng Y; Lu Y; Zhang Z; Guo C; Zhang G; Gou L; Yang J Mol Oncol; 2019 Sep; 13(9):1855-1873. PubMed ID: 31116512 [TBL] [Abstract][Full Text] [Related]
4. Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies. He K; Xu J; Liang J; Jiang J; Tang M; Ye X; Zhang Z; Zhang L; Fu B; Li Y; Bai C; Zhang L; Tao W Mol Cancer Ther; 2019 Jun; 18(6):1104-1114. PubMed ID: 30962319 [TBL] [Abstract][Full Text] [Related]
5. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037 [TBL] [Abstract][Full Text] [Related]
6. Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model. Gupta P; Jiang ZK; Yang B; Manzuk L; Rosfjord E; Yao J; Lemon L; Noorbehesht K; David J; Puthenveetil S; Casavant JM; Muszynska E; Li F; Leal M; Sapra P; Giddabasappa A MAbs; 2021; 13(1):1958662. PubMed ID: 34347577 [TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR). Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705 [TBL] [Abstract][Full Text] [Related]
8. A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects. Yang F; Zhao L; Wei Z; Yang Y; Liu J; Li Y; Tian X; Liu X; Lü X; Sui J J Immunol; 2020 Oct; 205(8):2156-2168. PubMed ID: 32887749 [TBL] [Abstract][Full Text] [Related]
9. Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. Burley TA; Mączyńska J; Shah A; Szopa W; Harrington KJ; Boult JKR; Mrozek-Wilczkiewicz A; Vinci M; Bamber JC; Kaspera W; Kramer-Marek G Int J Cancer; 2018 Jun; 142(11):2363-2374. PubMed ID: 29313975 [TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors. Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E MAbs; 2021; 13(1):1950264. PubMed ID: 34325617 [TBL] [Abstract][Full Text] [Related]
11. Construction of paclitaxel-based antibody-drug conjugates with a PEGylated linker to achieve superior therapeutic index. Shao T; Chen T; Chen Y; Liu X; Chen YL; Wang Q; Zhu T; Guo M; Li H; Ju D; Wang C Signal Transduct Target Ther; 2020 Jul; 5(1):132. PubMed ID: 32728048 [No Abstract] [Full Text] [Related]
12. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Jiang YP; Liu BY; Zheng Q; Panuganti S; Chen R; Zhu J; Mishra M; Huang J; Dao-Pick T; Roy S; Zhao X; Lin J; Banik G; Hsi ED; Mandalam R; Junutula JR Blood Adv; 2018 Jul; 2(14):1738-1749. PubMed ID: 30037800 [TBL] [Abstract][Full Text] [Related]
13. Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy. Godar M; Morello V; Sadi A; Hultberg A; De Jonge N; Basilico C; Hanssens V; Saunders M; Lambrecht BN; El Khattabi M; de Haard H; Michieli P; Blanchetot C Sci Rep; 2016 Aug; 6():31621. PubMed ID: 27546726 [TBL] [Abstract][Full Text] [Related]
14. VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Yu T; Chaganty B; Lin L; Xing L; Ramakrishnan B; Wen K; Hsieh PA; Wollacott A; Viswanathan K; Adari H; Cho SF; Li Y; Chen H; Yang W; Xu Y; An G; Qiu L; Munshi N; Babcock G; Shriver Z; Myette JR; Anderson KC; Tai YT Blood Cancer J; 2020 Nov; 10(11):110. PubMed ID: 33149123 [TBL] [Abstract][Full Text] [Related]
16. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer. Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. van de Water JA; Bagci-Onder T; Agarwal AS; Wakimoto H; Roovers RC; Zhu Y; Kasmieh R; Bhere D; Van Bergen en Henegouwen PM; Shah K Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16642-7. PubMed ID: 23012408 [TBL] [Abstract][Full Text] [Related]
18. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate. Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy. Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780 [TBL] [Abstract][Full Text] [Related]
20. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody". Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]